Role of ST2 in Non - ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

Clinical Chemistry

Volumn 58, Issue 1, 2012, Pages 257-266

  Kohli, Payal ^a,b   Bonaca, Marc P ^a,b   Kakkar, Rahul ^c   Kudinova, Anastacia Y ^b   Scirica, Benjamin M ^a,b   Sabatine, Marc S ^a,b   Murphy, Sabina A ^a   Braunwald, Eugene ^a,b   Lee, Richard T ^b   Morrow, David A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 1 RECEPTOR; MERLIN; PLACEBO; PROTEIN ST2; RANOLAZINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADRENAL DISEASE; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIAC PATIENT; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMODYNAMIC STRESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL STRESS; MUSCLE CELL; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ACETANILIDES; ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; INFLAMMATION; MALE; NATRIURETIC PEPTIDE, BRAIN; PIPERAZINES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CELL SURFACE; RISK ASSESSMENT;

EID: 84856074303     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.173369     Document Type: Article

References (36)

1. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277-81. (Pubitemid 34001295)
2. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;173:145-50. (Pubitemid 38797335)
3. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001;284:1104-8. (Pubitemid 32917952)
4. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468-73. (Pubitemid 38951733)
5. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007;149:217-25. (Pubitemid 47063063)
6. Trajkovic V, Sweet MJ, Xu D. T1/ST2: an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 2004;15:87-95. (Pubitemid 38523333)
7. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90. (Pubitemid 41587888)
8. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6. (Pubitemid 35424749)
9. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90. (Pubitemid 38625395)
10. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-44. (Pubitemid 351543469)
11. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011;161:1163-70.
12. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-83. (Pubitemid 46658646)
13. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52. (Pubitemid 47537839)
14. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006;151:1186 e1-9.
15. Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma: the Presage ST2 assay. Clin Chim Acta 2009;409:33-40.
16. Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll of Cardiol 2010;55:1189-96.
17. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38. (Pubitemid 47616190)
18. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, James SK. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010;159:788-94.
19. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21:128-38.
20. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999;264:397-406. (Pubitemid 29424443)
21. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49. (Pubitemid 46871338)
22. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-40.
23. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-46. (Pubitemid 351281600)
24. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52:1458-65.
25. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009;2:311-9.
26. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6. (Pubitemid 36222600)
27. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607-13. (Pubitemid 47199007)
28. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008;54:752-6. (Pubitemid 351573718)
29. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.
30. Shah RV, Januzzi JL Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 2010;7:9-14.
31. Grabowski M, Szymanski FM, Januzzi J, Wu AH, Hrynkiewicz-Szymanska A, Cacko A, et al. Prognostic utility of serial measurements of a novel biomarker ST2 in STEMI patients treated with primary PCI. American Heart Association: Scientific Sessions, Orlando, FL. Circulation 2009;120:S808.
32. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010;55:243-50.
33. Dinarello CA. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 2005;23:461-2. (Pubitemid 41587885)
34. Rossler U, Thomassen E, Hultner L, Baier S, Danescu J, Werenskiold AK. Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 1995;168:86-97.
35. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998;95:6930-5. (Pubitemid 28278084)
36. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009;2:684-91.